Clinical promise of next-generation complement therapeutics

Mastellos, Dimitrios C. and Ricklin, Daniel and Lambris, John D.. (2019) Clinical promise of next-generation complement therapeutics. Nature reviews. Drug discovery, 18 (9). pp. 707-729.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/73080/

Downloads: Statistics Overview


The complement system plays a key role in pathogen immunosurveillance and tissue homeostasis. However, subversion of its tight regulatory control can fuel a vicious cycle of inflammatory damage that exacerbates pathology. The clinical merit of targeting the complement system has been established for rare clinical disorders such as paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome. Evidence from preclinical studies and human genome-wide analyses, supported by new molecular and structural insights, has revealed new pathomechanisms and unmet clinical needs that have thrust a new generation of complement inhibitors into clinical development for a variety of indications. This review critically discusses recent clinical milestones in complement drug discovery, providing an updated translational perspective that may guide optimal target selection and disease-tailored complement intervention.
Faculties and Departments:05 Faculty of Science > Departement Pharmazeutische Wissenschaften > Pharmazie > Molekulare Pharmazie (Ricklin)
UniBasel Contributors:Ricklin, Daniel
Item Type:Article, refereed
Article Subtype:Research Article
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:31 Aug 2020 13:24
Deposited On:31 Aug 2020 13:24

Repository Staff Only: item control page